At a glance

ClinicalIndex Comparison Record

Phase 1Completed

Drug / intervention

SU101drug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00001573

NCT00001573Phase 1Completed

Compare CT.gov

A Phase I Study of SU101 in Pediatric Patients With Refractory Malignancy

National Cancer Institute (NCI)·interventional·Posted Dec 10, 2002·Updated Mar 4, 2008

In Brief

A Phase 1 clinical trial evaluating SU101 for Glioma and Sarcoma. Completed, across 1 site.

Detailed Summary

A dose escalation scale consisting of 5 dosage levels is being used to determine the maximum tolerated dose (MTD) of SU101. A minimum of 3 and a maximum of 6 patients will be enrolled at each dose level. MTD is defined as the dose level immediately below that at which 2 or more patients exhibit dose limiting toxicity. Each treatment cycle is 21 days. Patients receive a 96 hour continuous IV infusion of SU101 on days 1-4.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsGlioma, Sarcoma

CountriesUnited States

Collaborators--

Timeline

Phase 1CompletedFinished

1997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Enrollment StartMar 1997

Study CompletionMay 2000

First PostedDec 2002

TodayJul 2026

First PostedDec 10, 2002

Enrollment StartMar 1, 1997

Study CompletionMay 1, 2000

TodayJul 2, 2026

Posted 23.6 years ago

Interventions

SU101drug